Recently, a promising clinical antagonist GSK2193874, which possesses high TRPV4 affinity, has been shown to efficiently prevent and treat lung edema in heart failure models and congestive heart failure [62] (Table 2). This evidence concerns the gene TRPV4 and heart failure.